ABEO

ABEO

USD

Abeona Therapeutics Inc. Common Stock

$6.245+0.045 (0.726%)

Preço em tempo real

Healthcare
Biotecnologia
Estados Unidos

Gráfico de preços

Loading Chart...

Métricas-chave

Métricas de mercado
Fundamentos da empresa
Estatísticas de negociação

Métricas de mercado

Abertura

$6.200

Máximo

$6.310

Mínimo

$6.100

Volume

0.72M

Fundamentos da empresa

Capitalização de mercado

319.5M

Setor

Biotecnologia

País

United States

Estatísticas de negociação

Volume médio

1.67M

Bolsa de valores

NCM

Moeda

USD

Faixa de 52 semanas

Mínimo $3.93Atual $6.245Máximo $7.32

Notícias relacionadas

Analyst Upgrades

Oppenheimer Assumes Abeona Therapeutics at Outperform, Announces Price Target of $19

Oppenheimer analyst Andreas Argyrides assumes Abeona Therapeutics with a Outperform rating and announces Price Target of $19.

Ver mais
Oppenheimer Assumes Abeona Therapeutics at Outperform, Announces Price Target of $19
GlobeNewswire

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CLEVELAND, June 02, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in

Ver mais
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Analyst Upgrades

Stifel Maintains Buy on Abeona Therapeutics, Lowers Price Target to $20

Stifel analyst Dae Gon Ha maintains Abeona Therapeutics with a Buy and lowers the price target from $21 to $20.

Ver mais
Stifel Maintains Buy on Abeona Therapeutics, Lowers Price Target to $20
GlobeNewswire

Abeona Therapeutics® Reports First Quarter 2025 Financial Results and Corporate Updates

- Received approval by U.S. Food and Drug Administration (FDA) for ZEVASKYN™ (prademagenezamikeracel), the first and only autologous cell-based gene therapy for the treatment of wounds in adultand pediatric

Ver mais
Abeona Therapeutics® Reports First Quarter 2025 Financial Results and Corporate Updates
GlobeNewswire

UPDATE -- Abeona Therapeutics® and Lurie Children's Open First Center for ZEVASKYN™ Gene Therapy to Treat Wounds in Painful Skin Disorder

- ZEVASKYN, the first and only cell-based gene therapy for patients with recessive dystrophic epidermolysis bullosa (RDEB), now commercially available in the U.S. - - Ann & Robert H. Lurie Children's Hospital of

Ver mais
UPDATE -- Abeona Therapeutics® and Lurie Children's Open First Center for ZEVASKYN™ Gene Therapy to Treat Wounds in Painful Skin Disorder
GlobeNewswire

Abeona Therapeutics® and Lurie Children's Open First Center for ZEVASKYNTM Gene Therapy to Treat Wounds in Painful Skin Disorder

- ZEVASKYN, the first and only cell-based gene therapy for patients with recessive dystrophic epidermolysis bullosa (RDEB), now commercially available in the U.S. - - Ann & Robert H. Lurie Children's Hospital

Mantenha-se atualizado

Defina um alerta de preço, obtenha atualizações de análise de IA e notícias de mercado em tempo real.